Plazebo und Plazeboeffekte - Eine Bestandsaufnahme

Harald Walach; Catarina Sadaghiani

doi:10.1055/s-2002-33077

PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie, Table of Contents

Psychother Psychosom Med Psychol 2002; 52(8): 332-342
DOI: 10.1055/s-2002-33077

Originalarbeit

Plazebo und Plazeboeffekte - Eine Bestandsaufnahme

Placebo and Placebo Effects - A ReviewHarald Walach¹ , Catarina Sadaghiani¹

¹Universitätsklinikum Freiburg, Institut für Umweltmedizin und Krankenhaushygiene

Abstract

Zusammenfassung

Plazebogruppen in klinischen Studien dienen dazu, eine Reihe „unspezifischer” Effekte zu kontrollieren, um diesen die spezifischen Effekte der untersuchten Medikation gegenüberzustellen. Die Betonung spezifischer Effekte in der klinischen Forschung ist verständlich, geht es ihr um die Entdeckung neuer und wirksamer Arzneien. Diese Beschränkung in der klinischen Forschung vermittelte jedoch den Eindruck, die unspezifischen oder Plazeboeffekte seien therapeutisch wenig relevant. Im Folgenden wird der Plazebobegriff neu beleuchtet und es werden einige empirische Befunde dargestellt, die die Bedeutung von Plazeboeffekten unterstreichen. Die Befunde legen nahe, dass ein wertvoller therapeutischer Bestandteil jeglicher Intervention der Effekt ist, der auf die subjektive Bedeutung zurückgeht, die die Intervention für einen Patienten hat. Es werden einige Beispiele besprochen, wie solche unspezifischen Effekte therapeutisch maximiert werden können und welche Konsequenzen diese Betrachtungsweise für die Evaluation therapeutischer Maßnahmen hat.

Abstract

Placebo controls in clinical trials are usually employed to filter out undesired, psychological or non-specific effects from „true” therapeutic effects. Although this is useful in the context of clinical trials for the purpose of proving pharmacological efficacy, it is misleading to generalize this strategy to therapy as a whole. This would imply that placebo effects are irrelevant. Precisely this opinion is criticized in this paper. After some consideration about an appropriate notion of placebo, some empirical evidence is reviewed which underlines the importance of placebo effects. It is likely that the unspecific effects due to the individual meaning of an intervention are an important factor of any therapeutic approach. It would be therapeutically desirable to maximize these factors. This point of view would also have consequences on how interventions have to be evaluated.

Key words

Placebo - Placebo effect - Non-specific effects - Meaning

Full Text

References

Literatur

1 Beecher H K. The powerful placebo. JAMA. 1955; 159 1602-1606
2 Bodem S H. Bedeutung der Plazebowirkung in der praktischen Arzneitherapie. Pharmazeutische Zeitung. 1994; 139 4493-4503
3 Haas H, Fink H, Härtfelder G. Das Plazeboproblem. In: Jucker E (Hrsg) Fortschritte der Arzneimittelforschung. Basel; Birkhäuser 1959: 179-454
4 Meyer U A, Kindli R. Plazebos und Nozebos. Ther Umsch. 1989; 46 544-554
5 Netter P. Systematik der am Plazeboeffekt beteiligten Faktoren und Beispiele für ihre statistischen Wirkungen und Wechselwirkungen. In: Hippius H, Überla K, Laakmann G, Hasford J (Hrsg) Das Plazeboproblem. Stuttgart; Fischer 1986: 61-73
6 Piechowiak H. Die namenlose Pille. Über Wirkungen und Nebenwirkungen im therapeutischen Umgang mit Plazebopräparaten. Schweiz Med Wochenschr. 1981; 111 1222-1232
7 Turner J A, Deyo R A, Loeser J D. et al . The importance of placebo effects in pain treatment and research. JAMA. 1994; 20 1609-1614
8 Kienle G, Kiene H. Plazeboeffekt und Plazebokonzept - eine kritische methodologische und konzeptionelle Analyse von Angaben zum Ausmaß des Plazeboeffekts. Forsch Komplementärmed. 1996; 3 121-138
9 Kienle G S, Kiene H. The powerful placebo effect: fact or fiction? . J Clin Epidemiol. 1997; 50 1311-1318
10 Kienle G S. Der Plazeboeffekt - Realität oder Illusion. In: Hornung J (Hrsg) Forschungsmethoden in der Komplementärmedizin. Über die Notwendigkeit einer methodologischen Erneuerung. Stuttgart; Schattauer 1996: 84-97
11 Kienle G S. Der so genannte Plazeboeffekt. Illusion, Fakten, Realität. Stuttgart; Schattauer 1995
12 Kaptchuk T J. Intentional ignorance: a history of blind assessment and placebo controls in medicine. Bull Hist Med. 1998; 72 389-433
13 Kaptchuk T J. Powerful placebo: the dark side of the randomized controlled trial. Lancet. 1998; 351 1722-1725
14 Grünbaum A. The placebo concept in medicine and psychiatry. In: Shepherd M, Sartorius N (eds) Non-Specific Aspects of Treatment. Toronto, Lewiston, Bern, Stuttgart; Huber 1989: 7-38
15 Grünbaum A. The Plazebo effect in medicine and psychiatry. Psychol Med. 1986; 16 19-38
16 Grünbaum A. The placebo concept. Behav Res ther. 1981; 19 157-167
17 Shapiro A K. The placebo effect in medicine and psychological therapies. In: Morris LA, Garfield SL, Bergin A (eds) Handbook of Psychotherapy and Behavior Change: An Empirical Analysis. New York; Wiley 1978 2nd ed: 369-410
18 White L, Tursky B, Schwartz G E. Proposed synthesis of placebo models. In: White L, Tursky B, Schwartz GE (eds) Placebo. Theory, Research, and Mechanisms. New York; Guilford Press 1985: 431-447
19 Brody H. The doctor as therapeutic agent: a placebo effect research agenda. In: Harrington A (ed) The Placebo Effect: Interdisciplinary Explorations. Cambridge, MA; Harvard University Press 1997: 77-92
20 Brody H. Placebo effect: an examination of Grünbaum's definition. In: White L, Tursky B, Schwartz GE (eds) Placebo - Theory, Research, Mechanisms. New York; Guilford Press 1985: 37-58
21 Brody H. The symbolic power of the modern personal physician: The placebo response under challenge. Special issue: philosophies of drug giving and drug taking. Journal of Drug-Issues. 1988; 18 149-161
22 Moerman D E, Jonas W B. Toward a research agenda on placebo. Advances in Mind Body Medicine. 2000; 16 33-46
23 von Uexküll T. Biosemiotic research and not further molecular analysis is necessary to describe the pathways between cells, personalities, and social systems. Advances: The Journal of Mind-Body Health. 1995; 11 24-27
24 von Uexküll T. Die Bedeutung der Biosemiotik für die Medizin. Münchener Medizinische Wochenschrift. 1991; 133 601-602
25 von Uexküll T, Wesiack W. Theorie der Humanmedizin. Grundlagen ärztlichen Denkens und Handelns. München; Urban & Schwarzenberg 1988
26 Schonauer K. Plazebo Domino in Regione Vivorum - Über einige semiotische Grundmotive der arzneilichen Therapie. Karl und Veronica Carstens-Stiftung 1995 1: 142-154
27 Schonauer K. Semiotic Foundation of Drug Therapy: The Placebo Problem in a New Perspective. Berlin, New York; Mouton de Gruyter 1994
28 Kleijnen J, de Craen A JM, van Everdingen J, Krol L. Placebo effect in double-blind clinical trials: a review of interactions with medications. Lancet. 1994; 344 1347-1349
29 Bergmann J-F, Chassany O, Gandiol J. et al . A randomized clinical trial of the effect of informed consent on the analgesic activity of placebo and naproxen in cancer patients. Clinical Trials and Meta-Analysis. 1994; 29 41-47
30 Skovlund E. Should we tell trials patients that they might receive placebo?. Lancet. 1991; 337 1041
31 Skovlund E, Fyllingen G, Landre H, Nesheim B-I. Comparison of postpartum pain treatments using a sequential trial design I: paracetamol versus placebo. Eur J Clin Pharmacol. 1991; 40 343-347
32 Skovlund E, Fyllingen G, Landre H, Nesheim B-I. Comparison of postpartum pain treatments using a sequential trial design II: naproxen versus paracetamol. Eur J Clin Pharmacol. 1991; 40 539-542
33 Diener H C. Issues in migraine trial design: a case study (abstract). The 311C Symposium Presentations given in the 311C90 Symposion of the 3^rd European Headache Conference, 5 - 8 June 1996. S Margherita di Pula; 1996: 10-11
34 Diener H C, Klein K B. Multinational Oral 311C90 and Sumatriptan Comparative Study Group .The first comparison of the efficacy and safety of 311C90 and Sumatriptan in the treatment of migraine (abstract). 3rd European Headache Conference, 5. - 8. June 1996 S Margherita di Pula; 1996
35 Jhee S S, Salazar D E, Ford N F. et al . Monitoring of acute migraine attacks: placebo response and safety data. Headache. 1998; 38 35-38
36 Diener H C, Limmroth V. Therapie der akuten Migräneattacke und Migräneprophylaxe. Deutsche Medizinische Wochenschrift. 1998; 123 1449-1453
37 Diener H C, Dowson A J, Ferrari M. et al . Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia. 1999; 19 699-700
38 Butler C, Steptoe A. Placebo responses: an experimental study of psychophysiological processes in asthmatic volunteers. Br J Clin Psychol. 1986; 25 173-183
39 Hull J G, Bond C F. Social and behavioral consequences of alcohol consumption and expectancy: a meta-analysis. Psychol Bull. 1986; 99 347-360
40 Hedges L V, Olkin I. Statistical Methods for Meta-Analysis. Orlando; Academic Press 1985
41 Fillmore M, Vogel-Sprott M. Expected effect of caffeine on motor performance predicts the type of response to placebo. Psychopharmacology. 1992; 106 209-214
42 Fillmore M T, Mulvihill L E, Vogel-Sprott M. The expected drug and its expected effect interact to determine placebo responses to alcohol and caffeine. Psychopharmacology. 1994; 115 383-388
43 Hughes J F, Gulliver S B, Amori G. et al . Effects of instructions and nicotine on smoking cessation, withdrawal symptoms and self-administration of nicotine gum. Psychopharmacology. 1989; 99 486-491
44 Kirsch I, Rosadino M J. Do double-blind studies with informed consent yield externally valid results? An empirical test. Psychopharmacology. 1993; 110 437-442
45 Flaten M A, Blumenthal T D. Caffeine-associated stimuli elicit conditioned responses: an experimental model of the placebo effect. Psychopharmacology. 1999; 145 105-112
46 Walach H, Schmidt S, Wiesch S, Bihr N. The effects of subject and experimenter expectation on blood pressure, heart rate, wellbeing and cognitive performance: A failure to reproduce. European Psychologist. 2001; 6 15-25
47 Walach H, Schmidt S, Dirhold T, Nosch S. The effects of a caffeine placebo and suggestion on blood pressure, heart rate, wellbeing and cognitive performance: analysis of difficulties with reproducing. Int J Psychophysiol. 2002; 43 247-260
48 Kalauokalani D, Cherkin D C, Sherman K J. et al . Lessons from a trial of acupuncture and massage for low back pain. Spine. 2001; 26 1418-1424
49 Levine J D, Gordon N C. Influence of the method of drug administration on analgesic response. Nature. 1984; 312 755-756
50 Levine J D, Gordon N C, Smith R, Fields H L. Analgesic responses to morphine and placebo in individuals with postoperative pain. Pain. 1981; 10 379-389
51 Levine J D, Gordon N C, Bornstein J C, Fields H L. Role of pain in placebo analgesia. Proceedings of the National Academy of Science. 1979; 76 3528-3531
52 Levine J D, Gordon N C, Fields H L. Naloxone dose dependently produces analgesia and hyperalgia in postoperative pain. Nature. 1979; 278 740-741
53 Levine J D, Gordon N C, Fields H L. The mechanism of placebo analgesia. Lancet. 1978; II 654-657
54 Levine J D, Gordon N C, Jones R T, Fields H L. The narcotic antagonist naloxone enhances clinical pain. Nature. 1978; 272 826-827
55 Gracely R H, Dubner R, Deeter W R, Wolskee P J. Clinicians expectation influence placebo analgesia (letter). Lancet. 1985; I 43
56 Gracely R H, Dubner R, Wolskee P J, Deeter W R. Placebo and naloxone can alter post surgical pain by separate mechanisms. Nature. 1983; 306 264-265
57 Posner J, Burke C A. The effects of naloxone on opiate and placebo analgesia in healthy volunteers. Psychopharmacology. 1985; 87 468-472
58 Benedetti F. The opposite effects of the opiate antagonist naloxone and the cholecystokonin antagonist proglumide on placebo analgesia. Pain. 1996; 64 535-543
59 ter Riet G, de Craen A JM, de Boer A, Kessels A GH. Is placebo analgesia mediated by endogenous opiods? A systematic review. Pain. 1998; 76 273-275
60 Amanzio M, Benedetti F. Neuropharmacological dissection of placebo analgesia expectation-activated opioid systems versus conditioning-activated specific subsystems. J Neurosci. 1999; 19 484-494
61 Benedetti F, Amanzio M, Baldi S. et al . Inducing placebo respiratory depressant responses in humans via opioid receptors. Eur J Neurosci. 1999; 11 625-631
62 Benedetti F, Amanzio M, Baldi S. et al . The specific effects of prior opioid exposure on placebo analgesia and placebo respiratory depression. Pain. 1998; 75 313-319
63 Benedetti F, Amanzio M. The neurobiology of placebo analgesia: from endogenous opioids to cholecystekinin. Prog Neurobiol. 1997; 52 109-125
64 Benedetti F, Amanzio M, Maggi G. Potentiation of placebo analgesia by proglumide. Lancet. 1995; 346 1231
65 de la Fuente-Fernandez R, Ruth T J, Sossi V. et al . Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science. 2001; 293 1164-1166
66 Cobb L A, Thomas G I, Dillard D H, Merendino K A. et al . An evaluation of internal-mammary-artery ligation by a double-blind technique. N Engl J Med. 1959; 260 1115-1118
67 Beecher H K. Surgery as placebo. JAMA. 1961; 176 1102-1107
68 Moseley J B. Surgery as placebo (abstract). Conference Placebos and Nocebos - Developing a Research Agenda; Dec 4 - 5, 1996. Bethesda, MD; National Institute of Health 1996
69 Moseley J B, Wray N P, Kuykendall D. et al . Arthroscopic treatment of osteoarthritis of the knee: a prospective, randomized, placebo-controlled trial. Am J Sports Med. 1996; 24 28-34
70 Hrobjartsson A, Gotzsche P. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med. 2001; 344 1594-1602
71 Sinclair R, Cassuto J, Högström S. et al . Topical anaesthesia with lidocaine aerosol in the control of postoperative pain. Anaesthesiology. 1988; 68 895-901
72 Ross M, Olson J M. An expectancy attribution model of the effects of placebo. Psychol Rev. 1981; 88 408-437
73 Holroyd K A, Penzien D B. Pharmacological versus non-pharmacological prophylaxis of recurrent migraine headache. Pain. 1990; 42 1-13
74 Brill N Q. Results of psychotherapy. California Medicine. 1966; 104 249-253
75 Paul G L. Insight versus desensitisation in psychotherapy two years after termination. Journal of Consulting Psychology. 1967; 31 333-348
76 Keutzer C S. Behavior modification of smoking: the experimental investigation of diverse techniques. Behav Res ther. 1968; 6 137-157
77 Costello C G. The effects of depressants and stimulant drugs on the relationship between reaction time and stimulus light intensity. Brit J soc clin Psychol. 1963; 3 1-5
78 Kirsch I, Sapirstein G. Listening to prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention & Treatment http://journals apa org/prevention 1998 1: 2a
79 Walach H, Maidhof C. Is the placebo effect dependent on time?. In: Kirsch I (ed) How Expectancies shape Experience. Washington, DC; American Psychological Association 1999: 321-332
80 Wiesendanger H, Werthmüller L, Reuter K, Walach H. Chronically ill patients treated by spiritual healing improve in quality of life: results of a randomized waiting-list controlled study. Journal of Alternative and Complementary Medicine. 2001; 7 45-51
81 Alkaissi A, Stalnert M, Kalman S. Effect and placebo effect of acupressure (P6) on nausea and vomiting after outpatient gynaecological surgery. Acta Anaesthesiol Scand. 1999; 43 270-274
82 Helms J M. Acupuncture for the management of primary dysmenorrhea. Obstet Gynecol. 1987; 69 51-56
83 Montgomery G H, Tomoyasu N, Bovbjerg D H. et al . Patients' pretreatment expectations of chemotherapy-related nausea are an independent predictor of anticipatory nausea. Ann Behav Med. 1998; 20 104-109
84 Ivanovas G. Wissenschaftstheorie: Doppelblind bei alternativen Heilverfahren. Dt Ärztebl. 2001; 98 A822-825
85 Hahn R A. The nocebo phenomenon: scope and foundations. In: Harrington A (ed) The Placebo Effect. An Interdisciplinary Exploration. Cambridge, MA; Harvard University Press 1997: 56-76
86 DeMarco C W. On the impossibility of placebo effects in psychotherapy. Philosophical Psychology. 1998; 11 207-227
87 Wilkins W. Placebo controls and concepts in chemotherapy and psychotherapy research. In: White L, Tursky B, Schwartz GE (eds) Placebo. Theory, Research, and Mechanisms. New York; Guilford Press 1985: 83-109
88 Horvath P. Placebos and common factors in two decades of psychotherapy research. Psychol Bull. 1988; 104 214-225
89 Ruhmland M, Margraf J. Effektivität psychologischer Therapien von generalisierter Angststörung und sozialer Phobie: Metaanalysen auf Störungsebene. Verhaltenstherapie. 2001; 11 27-40
90 Frank J D. Non-specific aspects of treatment: the view of a psychotherapist. In: Shepherd M, Sartorius N (eds) Non-Specific Aspects of Treatment. Bern; Huber 1989: 95-114
91 Frank J D. Die Heiler: Wirkungsweisen psychotherapeutischer Beeinflussung; vom Schamanismus bis zu den modernen Therapien. Stuttgart; Klett-Cotta 1981
92 Coronary Drug Project Research Group . Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med. 1980; 303 1038-1041
93 Pincus T. Analyzing long-term outcomes of clinical care without randomized controlled clinical trials: The consecutive patient questionnaire database. Advances: The Journal of Mind-Body Health. 1997; 13 3-32
94 Thomas K B. The placebo in general practice. Lancet. 1994; 344 1066-1067
95 Thomas K B. General practice consultations: is there any point in being positive?. BMJ. 1987; 294 1200-1202
96 Shapiro A K, Shapiro E. The placebo: is it much ado about nothing. In: Harrington A (ed) The Placebo Effect: Interdisciplinary Explorations. Cambridge, MA; Harvard University Press 1997: 12-36
97 Köbberling J. Der Wissenschaft verpflichtet. Eröffnungsvortrag des Vorsitzenden des 103. Kongresses der Deutschen Gesellschaft für Innere Medizin, Wiesbaden, 6. April 1997. Medizinische Klinik. 1997; 92 181-189
98 Lowes T, Springer W. Nachlese zur Münchener homöopathischen Kopfschmerzstudie. Allgemeine Homöopathische Zeitung. 1997; 242 224-230
99 Klibansky R. Standing on the shoulders of the giants. Isis. 1936; 26 147-149
100 Grevert P, Albert L H, Goldstein A. Partial antagonism of placebo analgesia by naloxone. Pain. 1983; 16 129-143
101 Liberman R. An experimental study of the placebo response under three different situations of pain. J Psychiatr Res. 1964; 2 233-246
102 Lienert G A. Die Bedeutung der Suggestion in pharmakologischen Untersuchungen. Zeitschrift für experimentelle und angewandte Psychologie. 1955; 3 418-438
103 Gelfand S, Ullmann L P, Krasner L I. The placebo response: an experimental approach. J Nerv Ment Dis. 1963; 136 379-387
104 Sarles H, Camatte R, Sahel J. A study of the variations in the response regarding duodenal ulcer when treated with placebo by different investigators. Digestion. 1977; 16 289-292
105 Archer T P, Leier C V. Placebo treatment in congestive heart failure. Cardiology. 1992; 81 125-133
106 Hashish I, Ho K H, Harvey W. et al . Reduction of postoperative pain and swelling by ultrasound treatment: a placebo effect. Pain. 1988; 83 303-311
107 Hashish I, Harvey W, Harris M. Anti-inflammatory effects of ultrasound therapy: evidence for a major placebo effect. Br J Rheumatol. 1986; 25 77-81
108 Ho K H, Hashish I, Salmon P. et al . Reduction of post-operative swelling by a placebo effect. J Psychosom Res. 1988; 32 197-205
109 Mattarei M, De Venuto G, Dal Follo M, Miori R. Agisce il placebo nell’ipertensione arteriosa essenziale?. Minerva Cardioangiologica. 1985; 33 725-729
110 Nyboe Andersen A, Damm P, Tabor A. et al . Prevention of breast pain and milk secretion with bromocriptine after second-trimester abortion. Acta Obstet Gynecol Scand. 1990; 69 235-238
111 Klerman G L, Dimascio A, Weissman M. et al . Treatment of depression by drugs and psychotherapy. Am J Psychiatry. 1974; 131 186-191
112 Gay L, Carliner P. The prevention and treatment of motion sickness. Bulletin of the Johns Hopkins Hospital. 1949; 84 470-487
113 Tyler D B. The influence of a placebo, body position and medication of motion sickness. Am J Physiol. 1946; 146 458-466

PD Dr. Dr. phil. Harald Walach

Universitätsklinikum Freiburg · Institut für Umweltmedizin und Krankenhaushygiene

Hugstetterstraße 55

79106 Freiburg

Email: walach@ukl.uni-freiburg.de